INLB — Item 9 Labs Share Price
Last trade - 00:00- $0.00m
- $33.71m
- $21.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.06% | ||
| Return on Equity | -47.33% | ||
| Operating Margin | -110.94% | ||
Financial Summary
| Year End 30th Sep | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.4 | 4.93 | 8.12 | 21.94 | 21.76 | 23.5 | 30 | 186.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Item 9 Labs Corp. is a holding company investing in cannabis and cannabis-related businesses. The Company is a vertically integrated cannabis operator and dispensary franchisor delivering products from large-scale cultivation and production facilities in the U.S. The Company operates in two segments: Cultivation, which includes the cultivation, production, and sale of cannabis and cannabis-derived products and technologies distributed through licensed medical and adult-use dispensaries under its Item 9 Labs brand in Arizona, and Franchising, which involves the sales of franchises to dispensaries. It offers a dispensary franchise model through the national Unity Rd. retail brand. The Company offers approximately 75 active cannabis strains, more than 150 differentiated cannabis vaporizer (vape) products, concentrates, and Orion vape technologies. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.
Directors
- Douglas Bowden CHM (62)
- Andrew Bowden CEO (34)
- Robert Mikkelsen CFO (40)
- Christopher Wolven COO (40)
- Jeffrey Rassas OTH (59)
- Michael Weinberger DRC (44)
- Eric Kutscher IND (46)
- Lawrence Taylor IND (57)
- Last Annual
- September 30th, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- June 15th, 2010
- Public Since
- November 3rd, 2011
- No. of Shareholders
- 2,904
- No. of Employees
- 97
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 102,362,271
- Address
- 2111 E HIGHLAND AVE, SUITE B375, PHOENIX, 85016
- Web
- https://item9labscorp.com/
- Phone
- +1 4804634246
- Auditors
- BF Borgers CPA PC
Upcoming Events for INLB
Similar to INLB
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 21:24 UTC, shares in Item 9 Labs are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Item 9 Labs last closed at $0.00 and the price had moved by -99.75% over the past 365 days. In terms of relative price strength the Item 9 Labs share price has underperformed the S&P500 Index by -99.77% over the past year.
The overall consensus recommendation for Item 9 Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreItem 9 Labs does not currently pay a dividend.
Item 9 Labs does not currently pay a dividend.
Item 9 Labs does not currently pay a dividend.
To buy shares in Item 9 Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Item 9 Labs had a market capitalisation of $0.00m.
Here are the trading details for Item 9 Labs:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: INLB
Based on an overall assessment of its quality, value and momentum Item 9 Labs is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Item 9 Labs is $4.00. That is 399999900% above the last closing price of $0.00.
Analysts covering Item 9 Labs currently have a consensus Earnings Per Share (EPS) forecast of -$0.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Item 9 Labs. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Item 9 Labs were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Item 9 Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Item 9 Labs' management team is headed by:
- Douglas Bowden - CHM
- Andrew Bowden - CEO
- Robert Mikkelsen - CFO
- Christopher Wolven - COO
- Jeffrey Rassas - OTH
- Michael Weinberger - DRC
- Eric Kutscher - IND
- Lawrence Taylor - IND